Forge Biologics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2020-01-01
- Employees
- 251
- Market Cap
- -
Clinical Trials
4
Active:4
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Forge Biologics, Inc
- Target Recruit Count
- 25
- Registration Number
- NCT06308718
- Locations
- 🇺🇸
University of Michigan Hospitals - Michigan Medicine, Ann Arbor, Michigan, United States
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Forge Biologics, Inc
- Target Recruit Count
- 9
- Registration Number
- NCT05739643
- Locations
- 🇺🇸
Children's Hospital of Orange County (CHOC), Orange, California, United States
🇺🇸University of Michigan Hospitals - Michigan Medicine, Ann Arbor, Michigan, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Gene Transfer Clinical Trial for Krabbe Disease
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Forge Biologics, Inc
- Target Recruit Count
- 6
- Registration Number
- NCT04693598
- Locations
- 🇺🇸
University of Michigan Hospitals - Michigan Medicine, Ann Arbor, Michigan, United States
News
No news found